Morgan Stanley
MSLE

Morgan Stanley’s Satellos Bioscience MSLE Stock Holding History

Morgan Stanley’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Buy
25,732
+4,549
+21% +$31.3K ﹤0.01% 5954
2026
Q1 		$119K Buy
+21,183
New +$208K ﹤0.01% 6079

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Morgan Stanley's MSLE Position: Q2 2026 in Review

Morgan Stanley increased its Satellos Bioscience (MSLE) stake by 21% in Q2 2026, buying an estimated $31.3K and bringing the position to 25,732 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #5954.

Morgan Stanley first reported a position in MSLE in Q1 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold MSLE as of Q2 2026.

  • Morgan Stanley held 25,732 shares of Satellos Bioscience worth $200K as of Q2 2026.
  • Morgan Stanley bought 4,549 Satellos Bioscience shares in Q2 2026, an estimated $31.3K.
  • Satellos Bioscience made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5954 holding.
  • Morgan Stanley first reported a position in Satellos Bioscience in Q1 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Satellos Bioscience as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.